On September 26, 2023, Avalo Therapeutics, Inc. closed the transaction. The company received $5 million in its third and final tranche. The transaction bringing total funding to $35 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.92 USD | -1.62% | +3.02% | +20.00% |
May. 13 | Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.00% | 11.48M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- AVTX Stock
- News Avalo Therapeutics, Inc.
- Avalo Therapeutics, Inc. announced that it has received $35 million in funding from Horizon Technology Finance Management, LLC